Multidrug Resistance Related Proteins in Primary Cutaneous Lymphomas

  • Christian W. van Haselen
  • Marcel J. Flens
  • Rik J. Scheper
  • Paul van der Valk
  • George L. Scheffer
  • Johan Toonstra
  • Willem A. van Vloten
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 457)

Abstract

In patients with primary cutaneous B-cell lymphomas (CBCL) and primary cutaneous T-cell lymphomas (CTCL), extracutaneous sites may become involved and then polychemotherapy is indicated. Multi-agent chemotherapy may induce long lasting complete remissions in CBCL’s. Most CTCL’s, especially mycosis fungoides (MF), and CD30 negative primary cutaneous large T-cell lymphoma (PCLTCL) respond poorly or partially to Multi-agent Chemotherapy.

Keywords

cutaneous lymphomas P-glycoprotein multidrug resistance protein lung resistance protein 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S, Diaz-Peréz JL, Geerts ML, Goos M, Knobler R, Ralfkiaer E, Santucci M, Smith N, Wechsler J, Van Vloten WA, Meijer CJLM. EORTC classification for primary cutaneous lymphomas: A proposal from the cutaneous lymphomas study group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90:354–71.PubMedGoogle Scholar
  2. 2.
    Kay FJ, Bunn PA, Steinberg SM. A randomized trial comparing combination electron beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989; 321, 1784.CrossRefGoogle Scholar
  3. 3.
    Pui C, Relling MV, Mason E, Rivera GK, Crist WM, Evans WE. Pharmacokinetic resistance in childhood leukaemia. In: drug resistance in leukaemia and lymphoma II. Eds. R. Pieters, GJL Kaspers and AJP Veerman. Harwood Academic Publishers 1997 The Netherlands pp 1–7.Google Scholar
  4. 4.
    Rossi JF. Biological and clinical aspects of chemoresistance. Part 2: leukaemias. Retinoids today and tomorrow 1996; 45:28–31.Google Scholar
  5. 5.
    Yuen AR, Sikic BI. Multidrug resistance in lymphomas. J Clin Oncol 1994; 12:2453–2459.PubMedGoogle Scholar
  6. 6.
    Landowski TH, Gleason-Guzman MC, Dalton WS. Selection for drug resistance results in resistance to fas-mediated apoptosis. Blood 1997; 89:1854–1861.PubMedGoogle Scholar
  7. 7.
    den Boer ML, Zwaan MC, Pieters R, Kazemier KM, Rottier MMA, Flens MJ, Scheper RJ and Veerman AJ. Optimal immunocytochemical and flow cytometric detection of Pgp, MRP and LRP in childhood acute lymphoblastic leukemia. Leukemia 1997; 11:1078–1085.CrossRefGoogle Scholar
  8. 8.
    Marie JP. P-glycoprotein in adult hematologic malignancies. Hematology/oncology clinics of North-America 1995; 9:239–248.PubMedGoogle Scholar
  9. 9.
    Legrand O, Perrot JY, Tang R, Simonin G, Gurbuxani S, Zittoun R, Marie JP. Expression of the multidrug resistance-associated protein (MRP) MRNA and protein in normal peripheral blood and bone marrow haemopoietic cells. Br J Haematol 1996; 94:23–33.PubMedCrossRefGoogle Scholar
  10. 10.
    Flens MJ, Izquierdo MA, Scheffer GL, Fritz JM, Meijer CJLM, Scheper RJ and Zaman GJR. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res 1994; 54:4557–4563.PubMedGoogle Scholar
  11. 11.
    Nooter K, Westerman MA, Flens MJ, Zaman GJR, Scheper RJ, van Wingerden KE, Burger H, Oostrum R, Boersma T, Sonneveld P, Gratema JW, Kok T, Eggermont AMM, Bosman FT and Stoter G. Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res 1995; 147:1545–1552.Google Scholar
  12. 12.
    Flens MF, Zaman GJR, van der Valk P, Izquierdo MA, Schroeijers AB, Scheffer GL, van der Groep P, de Haas M, Meijer CJLM and Scheper RJ. Tissue distribution of the multidrug resistance protein. Am J Pathol 1996; 148:1237–1247.PubMedGoogle Scholar
  13. 13.
    Zhan Z, Sandor VA, Gamelin E, Regis J, Dickstein B, Wilson W, Fojo AT, Bates SE. Expression of the multidrug resistance-associated protein gene in refractory lymphoma: Quantitation by a validated polymerase chain reaction assay. Blood 1997; 89:3795–3800.PubMedGoogle Scholar
  14. 14.
    Izquierdo MA, Scheffer GL, Flens MF, Schroeijers AB, van der Valk P and Scheper RJ. Major vault protein LRP-related multidrug resistance. Eur J Cancer 1996; 32A: 979–984.PubMedCrossRefGoogle Scholar
  15. 15.
    Izquierdo MA, Scheffer GL, Flens MJ, Giaccone G, Broxterman HJ, Meijer CJLM, van der Valk P and Scheper RJ. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol 1996; 148:877–887.PubMedGoogle Scholar
  16. 16.
    Wilson WH, Bates SE, Fojo A, Bryant G et al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 1995; 13:1995–2004.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • Christian W. van Haselen
    • 1
    • 3
  • Marcel J. Flens
    • 2
  • Rik J. Scheper
    • 2
  • Paul van der Valk
    • 2
  • George L. Scheffer
    • 2
  • Johan Toonstra
    • 1
  • Willem A. van Vloten
    • 1
  1. 1.Department of DermatologyUniversity Hospital UtrechtThe Netherlands
  2. 2.Department of PathologyUniversity Hospital Vrije UniversiteitAmsterdamThe Netherlands
  3. 3.Department of DermatologyUniversity Hospital UtrechtUtrechtThe Netherlands

Personalised recommendations